002327SZSE

Independent Director's 2025 Annual Performance Report (Lin Li)

✨ AI Summary

This report details the performance of Independent Director Lin Li for the year 2025. It covers attendance at board and shareholder meetings, participation in special committees, and communication with stakeholders. The director fulfilled duties diligently, focusing on protecting shareholder interests and ensuring corporate governance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Shenzhen Glorious Home Furnishings Co., Ltd.

Independent Director's 2025 Annual Performance Report

— Lin Li

To all shareholders and shareholder representatives:

As an independent director of Shenzhen Glorious Home Furnishings Co., Ltd. (hereinafter referred to as the "Company"), during my term of office in 2025, I strictly followed the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Guiding Opinions on the Establishment of Independent Directors System for Listed Companies," and other laws and regulations, Shenzhen Stock Exchange business rules, and the "Articles of Association of Shenzhen Glorious Home Furnishings Co., Ltd." (hereinafter referred to as the "Articles of Association"), and the "Work System for Independent Directors" and other internal company rules. I conscientiously exercised my powers, played the role of an independent director, maintained the standardized operation of the company and the legitimate rights and interests of shareholders, and fulfilled the duties and responsibilities of an independent director. Herein is a report on my fulfillment of independent director duties in 2025:

I. Basic Information of Independent Director

(I) Work Experience, Professional Background, and Concurrent Positions of Independent Director

I, Lin Li, born in 1969, hold a bachelor's degree, and am a certified public accountant and economist. I have obtained the qualification certificate for independent directors recognized by the Shenzhen Stock Exchange. From 2013 to the present, I have served as the Deputy General Manager and Secretary of the Board of Directors of Shenzhen Shangrong Medical Co., Ltd. (002551.SZ). I have also served as a director of Suzhou Jimeirui Medical Devices Co., Ltd., and currently serve as a supervisor of Hefei Purde Medical Supplies Co., Ltd. and a supervisor of Zhangjiagang Jinzhou Medical Device Manufacturing Co., Ltd. I have served as an independent director of the Company since October 2024.

(II) Statement of Independence

During my tenure, I have not held any positions in the Company other than independent director and member of the Board of Directors' special committees. I have also not held any positions in the principal shareholders' companies. There are no relationships of interest or other relationships that may hinder independent and objective judgment between myself and the Company or its principal shareholders, which meets the requirements of laws and regulations such as the "Guiding Opinions on the Establishment of Independent Directors System for Listed Companies" and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 — Standardized Operation of Main Board Listed Companies" regarding the qualifications and independence of independent directors. There are no circumstances that affect my independence.

II. Overview of Independent Director's Performance in the Reporting Period

Independent Director NameNumber of Board Meetings to AttendNumber of Board Meetings AttendedNumber of Entrusted Board MeetingsNumber of Absent Board MeetingsWhether Attended Two Consecutive Board Meetings in PersonNumber of Shareholder Meetings Attended
Lin Li7700No4

During the reporting period, I conscientiously attended the Company's board meetings and shareholder meetings, faithfully performed my duties. The convening and holding of board meetings and shareholder meetings complied with legal procedures. Major operating decisions were made in accordance with relevant procedures and were legal and effective. In 2025, the Company held 7 board meetings and 4 shareholder meetings.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.